%0 Journal Article
%T Oncolytic virus and PD-1/PD-L1 blockade combination therapy
%A Brian Hutzen
%A Chun-Yu Chen
%A Mary F Wedekind
%A Timothy P Cripe
%J Archive of "Oncolytic Virotherapy".
%D 2018
%R 10.2147/OV.S145532
%X Oncolytic viruses are lytic for many types of cancers but are attenuated or replication-defective in normal tissues. Aside from tumor lysis, oncolytic viruses can induce host immune responses against cancer cells and may thus be viewed as a form of immunotherapy. Although recent successes with checkpoint inhibitors have shown that enhancing antitumor immunity can be effective, the dynamic nature of the immunosuppressive tumor microenvironment presents significant hurdles to the broader application of these therapies. Targeting one immune-suppressive pathway may not be sufficient to eliminate tumors. Here we focus on the development of the combination of oncolytic virotherapy with checkpoint inhibitors designed to target the programmed cell death protein 1 and programmed cell death ligand 1 signaling axis. We also discuss future directions for the clinical application of this novel combination therapy
%K cancer
%K viral oncolysis
%K immunotherapy
%K immune checkpoint blockade
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6074764/